Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2 two-part open label trial of ISA103 in combination with standard of care checkpoint blocker immunotherapies

Next Previous
Trial Profile

Phase 1b/2 two-part open label trial of ISA103 in combination with standard of care checkpoint blocker immunotherapies

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 05 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ISA 103 (Primary) ; Immune checkpoint protein inhibitors
  • Indications Uveal melanoma
  • Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use

Most Recent Events

  • 05 Jan 2023 New trial record
  • 04 Jan 2023 According to an ISA Pharmaceuticals media release, the ISA Pharmaceuticals and Cancer Focus Fund, LP is investing $5 million in funding to support this trial.
  • 04 Jan 2023 According to an ISA Pharmaceuticals media release, the trial will be conducted at MD Anderson under the direction of Principal Investigator Sapna Patel.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top